Some individuals experience severe nausea, vomiting, or gastrointestinal distress on semaglutide that does not resolve with dose adjustments
The table below is built from the published trial protocols
Arkansas -1.4% Arkansas likely saw a drop in GLP-1 prescriptions in 2024 due to Medicaid and state employee plans refusing to cover them for weight loss, strict prior authorization rules even for diabetes use, and ongoing drug shortages
PlexusDx clinicians monitor your progress and adjust dosing to maximize benefit
This pricing model removes the financial anxiety many patients feel about needing dose increases for optimal results
At the time of the switch, a subset of patients expressed concerns about the long-term impact that it would have on their condition management, and in an online survey many stated that they were dissatisfied with the level of care received